CN110327472B - Multifunctional targeted ultrasound contrast agent and preparation method thereof - Google Patents
Multifunctional targeted ultrasound contrast agent and preparation method thereof Download PDFInfo
- Publication number
- CN110327472B CN110327472B CN201910615944.2A CN201910615944A CN110327472B CN 110327472 B CN110327472 B CN 110327472B CN 201910615944 A CN201910615944 A CN 201910615944A CN 110327472 B CN110327472 B CN 110327472B
- Authority
- CN
- China
- Prior art keywords
- contrast agent
- polylactic acid
- ultrasonic
- glycolic acid
- acid copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002961 echo contrast media Substances 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000002872 contrast media Substances 0.000 claims abstract description 42
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims abstract description 37
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims abstract description 37
- YCUVUDODLRLVIC-UHFFFAOYSA-N Sudan black B Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1N=NC(C1=CC=CC=C11)=CC=C1N=NC1=CC=CC=C1 YCUVUDODLRLVIC-UHFFFAOYSA-N 0.000 claims abstract description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 25
- 238000004945 emulsification Methods 0.000 claims abstract description 16
- 239000004005 microsphere Substances 0.000 claims abstract description 16
- 230000008878 coupling Effects 0.000 claims abstract description 12
- 238000010168 coupling process Methods 0.000 claims abstract description 12
- 238000005859 coupling reaction Methods 0.000 claims abstract description 12
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000012190 activator Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 54
- 229920001577 copolymer Polymers 0.000 claims description 39
- 239000007987 MES buffer Substances 0.000 claims description 31
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 15
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 11
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 10
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 10
- 239000001099 ammonium carbonate Substances 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 238000000265 homogenisation Methods 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 6
- 239000012154 double-distilled water Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000003760 magnetic stirring Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 18
- 238000003384 imaging method Methods 0.000 abstract description 16
- 210000005073 lymphatic endothelial cell Anatomy 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 11
- 239000001045 blue dye Substances 0.000 abstract description 9
- 239000000975 dye Substances 0.000 abstract description 9
- 230000008685 targeting Effects 0.000 abstract description 9
- 206010027476 Metastases Diseases 0.000 abstract description 8
- 230000009401 metastasis Effects 0.000 abstract description 8
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 229920000747 poly(lactic acid) Polymers 0.000 abstract 5
- 239000004626 polylactic acid Substances 0.000 abstract 5
- 210000001165 lymph node Anatomy 0.000 description 25
- 210000005005 sentinel lymph node Anatomy 0.000 description 11
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 210000001365 lymphatic vessel Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 4
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 4
- 230000035168 lymphangiogenesis Effects 0.000 description 4
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 3
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 241001413591 Trifolium arvense Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000001698 popliteal fossa Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a multifunctional targeted ultrasound contrast agent, which comprises carboxyl-terminated polylactic acid, wherein fluorocarbon gas is filled in the carboxyl-terminated polylactic acid to form carboxyl-terminated polylactic acid microspheres, Sudan black dye is loaded in the carboxyl-terminated polylactic acid, and an antihuman VEGFR-3 monoclonal antibody is coupled at the carboxyl terminal of the carboxyl-terminated polylactic acid through a covalent bond. The contrast agent can be more accurately and effectively positioned and firmly combined on the surface of lymphatic endothelial cells, has stronger targeting capability, has ultrasonic contrast imaging and intraoperative indication functions, has the effect of preventing tumor metastasis, and is a multifunctional ultrasonic contrast agent which gives consideration to both blue stain tracing effect and ultrasonic imaging effect and treatment. The invention also discloses a preparation method of the contrast agent, the ultrasonic contrast agent with the blue dye indication function is prepared by using a double-emulsion method, EDC/NHS is used as a coupling activator, VEGFR-3 is covalently connected on the surface of the ultrasonic contrast agent, and the method is simple, easy to operate and suitable for large-scale production.
Description
Technical Field
The invention belongs to the technical field of biotechnology and medicine, and particularly relates to a multifunctional targeted ultrasound contrast agent and a preparation method thereof.
Background
In clinical practice, the search for a tumor sentinel node generally employs two approaches: one method is a radionuclides tracing method, such as dextran, plasma protein, etc., labeled with the radioactive isotope technetium 99m, which can be detected in the human body by a radioactive detector; another method is reactive blue dye tracing, such as with methylene blue, isoschulvin, etc., which can stain lymph nodes blue and thus be found during surgery. Although the two methods are clinically used up to now, the two methods also have many defects, such as strong radiation, low image spatial resolution detected by a radioactive detector, incapability of accurately positioning for surgery, and the like; in addition, since the isotope is labeled with a small molecule substance, it inevitably enters the second lymph node to cause inaccurate labeling of the sentinel lymph nodes. And part of the dye can cause allergic reaction of part of patients; in some patients, the sentinel lymph nodes are too close to the non-sentinel lymph nodes to distinguish them from the blue stain, so that the non-sentinel lymph nodes are excessively excised; the blue dye has small molecular weight, is easy to penetrate through lymphatic capillaries to reach the capillaries, so as to cause skin pigmentation and pseudo-hypoxemia, further cause the interference of misreading of a pulse oximeter during operation, and even more particularly, develop pseudo-methemoglobinemia.
Therefore, the multifunctional ultrasonic contrast agent which can accurately observe obviously enhanced tumor metastasis lymph nodes in an ultrasonic contrast mode, accurately indicate sentinel lymph nodes in an operation and reduce side effects is developed, and the multifunctional ultrasonic contrast agent has very important practical significance in the technical field.
With recent advances in the study of tumor-associated lymphangiogenesis and lymphatic metastasis mechanisms, VEGFR-3 has been recognized as being critical in determining lymphangiogenesis responses. The VEGF-C/VEGFR-3 or VEGF-D/VEGFR-3 signaling pathways play important regulatory roles in the lymphatic angiogenesis process. Under the action of VEGF-C, the endothelial cells of the lymphatic vessels around the tumor migrate into the tumor and grow to form new lymphatic vessels. VEGFR-3 is highly expressed in tumors that have undergone lymphatic metastasis, targeting VEGFR-3 helps to label the tumor and the pathways of lymphatic metastasis. Yulong He and his team have demonstrated in studies that blocking VEGFR-3 receptors can prevent lymph node metastasis of tumors in a dose-dependent manner early in the lymph node spread of tumors. The anti-VEGFR-3 antibody can be expressed in lymphatic endothelial cells and partial tumor cells. Due to the rapid growth of tumor cells, the mechanical pressure and osmotic pressure in the tumor are obviously increased, and the peripheral lymphatic vessels are not easy to extend into the tumor tissue, so that the lymphatic vessels in the tumor are sparser and collapse than the peripheral lymphatic vessels. Lymphangiogenesis occurs mainly at and around the periphery of the tumor, with a lack or absence of lymphangiogenesis in the central part of the tumor. Therefore, targeting microvesicles with anti-human VEGFR-3 monoclonal antibodies can selectively attach to lymphatic endothelial cells or some cancer cells, and also have the potential to disrupt the VEGF-C/VEGFR-3 or VEGF-D/VEGFR-3 signaling system, preventing tumor metastasis. However, the anti-human VEGFR-3 monoclonal antibody only has a targeting effect, and how to specifically realize tumor labeling and lymphatic metastasis tracking by combining ultrasonic contrast imaging and intraoperative indication functions is a problem to be solved in the technical field.
Disclosure of Invention
The technical problem to be solved by the invention is to overcome the defects and shortcomings in the background technology and provide a multifunctional targeted ultrasound contrast agent and a preparation method thereof.
In order to solve the technical problems, the technical scheme provided by the invention is to provide a multifunctional targeted ultrasound contrast agent, which comprises polylactic acid-glycolic acid copolymer (PLGA-COOH), wherein fluorocarbon gas is filled in the polylactic acid-glycolic acid copolymer to form polylactic acid-glycolic acid copolymer microspheres, Sudan black dye is loaded in the polylactic acid-glycolic acid copolymer, and an anti-human VEGFR-3 monoclonal antibody is coupled to the carboxyl terminal (-COOH) of the polylactic acid-glycolic acid copolymer through a covalent bond.
Polylactic-co-glycolic acid (PLGA-COOH) is a biodegradable and biocompatible polymer, non-toxic and highly efficient in delivery, can be used as an ultrasound contrast agent, enables ultrasound images to be significantly enhanced, and the PLGA-COOH microparticles have high acoustic efficacy, which remains stable over time. And the surface of PLGA-COOH contains a large number of carboxyl, while the anti-human VEGFR-3 monoclonal antibody is a protein substance and contains a large number of amino, and the carboxyl and the amino can be coupled and combined through covalent bonds. Sudan black is a fat-soluble dye, can be effectively combined with hydrophobic PLGA-COOH and dyes the PLGA-COOH into blue, and can replace active blue dyes (such as methylene blue and the like) which are used continuously in clinic. The fluorocarbon gas can enhance the scattering effect of the multifunctional targeted ultrasound contrast agent on ultrasonic waves, and the multifunctional targeted ultrasound contrast agent is clinically injected into a human blood vessel to enhance the ultrasonic Doppler signal of blood flow and improve the definition and resolution of an ultrasonic image.
Loading fat-soluble blue dye Sudan black on PLGA to realize the ultrasonic contrast imaging and intraoperative indication functions of the contrast agent; meanwhile, the anti-human VEGFR-3 monoclonal antibody is covalently coupled on the surface of the PLGA, so that the antibody can be more accurately and effectively positioned and firmly combined on the surface of lymphatic endothelial cells, and has a stronger targeting function; in addition, the anti-human VEGFR-3 monoclonal antibody also has the potential capability of destroying a VEGF-C/VEGFR-3 or VEGF-D/VEGFR-3 signal system, and also has a certain effect of preventing tumor metastasis after the VEGFR-3 receptor of a lymphatic endothelial cell is blocked. The contrast agent can reach a first lymph node along a nearby lymphatic vessel after being injected under the skin, and is positioned and combined on the surface of an endothelial cell of the lymphatic vessel, so that the obviously enhanced tumor metastasis lymph node can be observed in an ultrasonic contrast mode, a sentinel lymph node can be indicated in the operation, a long-circulating and automatic-targeting multifunctional nano imaging system is realized, the contrast agent is a multifunctional ultrasonic contrast agent which gives consideration to the blue stain tracing effect, the ultrasonic imaging effect and the treatment, and the contrast agent can be applied to the ultrasonic imaging of the sentinel lymph node before the operation and the imaging and positioning of the lymph node in the operation.
Preferably, the particle size of the microsphere of the multifunctional targeted ultrasound contrast agent is 1-2 μm; the polymerization ratio of carboxyl and hydroxyl in the polylactic acid-glycolic acid copolymer is 50: 50.
Based on a general technical concept, the invention also correspondingly provides a preparation method of the multifunctional targeted ultrasound contrast agent, which comprises the following steps:
(1) dissolving a polylactic acid-glycolic acid copolymer in dichloromethane, adding Sudan black, and stirring until the mixture is completely dissolved to obtain a mixed solution;
(2) adding an ammonium carbonate solution into the mixed solution obtained in the step (1), performing ultrasonic emulsification to obtain a primary emulsion, adding a polyvinyl alcohol solution, and performing homogenization treatment to obtain a double emulsion;
(3) adding an isopropanol solution into the double emulsion obtained in the step (2), performing magnetic stirring, centrifuging, washing the precipitate with double distilled water, and performing vacuum freeze drying to obtain the polylactic acid-glycolic acid copolymer-loaded Sudan black non-targeted ultrasonic contrast agent;
(4) dispersing and dissolving the non-targeted ultrasound contrast agent obtained in the step (3) in an MES buffer solution, adding a coupling activator EDC/NHS for incubation, then centrifuging in the MES buffer solution, and removing unreacted EDC/NHS after rinsing to obtain a macromolecular contrast agent;
(5) and (4) dispersing and dissolving the macromolecular contrast agent obtained in the step (4) in an MES buffer solution, adding an anti-human VEGFR-3 monoclonal antibody, uniformly mixing, incubating, centrifuging in the MES buffer solution, rinsing, taking the precipitate, performing vacuum freeze drying, and then filling fluorocarbon gas to obtain the multifunctional targeted ultrasound contrast agent.
EDC/NHS (EDC is 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and NHS is N-hydroxysuccinimide) coupling activator capable of linking carboxyl groups of PLGA-COOH and amino groups of anti-human VEGFR-3 monoclonal antibody (which is a protein) through an amide bond by reaction, was used as a coupling activator purchased from Sigma in the USA. And EDC can be used in water phase, and the synthesized PLGA-COOH coated Sudan black non-targeted ultrasound contrast agent is also water-soluble and has good compatibility.
In the preparation method, preferably, in the step (1), the ratio of the mass of the polylactic acid-glycolic acid copolymer to the volume of the dichloromethane is 50: 1 in mg/mL, and in the step (1), the ratio of the mass of the sudan black to the volume of the dichloromethane is 2: 1 in mg/mL.
Preferably, in the step (2), the mass concentration of the ammonium carbonate solution is 4%, the volume ratio of the ammonium carbonate solution to dichloromethane is 1: 10, the power of ultrasonic emulsification is 110W, and the time of ultrasonic emulsification is 30-40 s; the mass concentration of the polyvinyl alcohol solution is 4%, the volume ratio of the polyvinyl alcohol solution to the dichloromethane solvent is 5: 1, the rotation speed of homogenization treatment is 9000-10000 rpm, and the time of the homogenization treatment is 5-8 min.
Preferably, in the step (3), the mass concentration of the isopropanol solution is 2%, the volume ratio of the isopropanol solution to the dichloromethane solvent is 10: 1, and the magnetic stirring time is 2-3 h.
Preferably, in the step (4), the pH value of the MES buffer solution is 5.9-6.3, the incubation temperature is 0-4 ℃, the incubation time is 120-130 min, the centrifugal speed is 3000-5000 rpm, and the rinsing frequency is 3-5 times; in the step (5), the pH value of the MES buffer solution is 7.9-8.3, the incubation temperature is 0-4 ℃, the incubation time is 60-70 min, the centrifugal speed is 3000-5000 rpm, and the rinsing times are 3-5 times.
Preferably, in the step (4), the mass ratio of EDC to NHS is 1: 3; the mass ratio of EDC to non-targeted ultrasound contrast agent is 1: 10.
Preferably, in the step (5), the mass ratio of the anti-human VEGFR-3 monoclonal antibody to the macromolecular contrast medium is 1: 2000.
Preferably, in the step (3) and/or the step (5), the temperature of vacuum freeze drying is-80 ℃, and the time of vacuum freeze drying is 40-50 h.
According to the invention, by utilizing a double emulsification method and a vacuum freeze drying technology, fat-soluble blue dye Sudan black is added into a PLGA ultrasonic contrast agent, the Sudan black is loaded on a PLGA ultrasonic microbubble wall to prepare the ultrasonic contrast agent SB-PLGA with the blue dye indication function, and VEGFR-3 is covalently connected on the surface of the ultrasonic contrast agent SB-PLGA, so that the macromolecular contrast agent can be more accurately, more effectively positioned and firmly combined on the surface of lymphatic endothelial cells, and has stronger targeting capability. Before the operation, the internal structure of the lymph node can be displayed through ultrasonic enhancement, and under the operation visual field, the sentinel lymph node can be accurately determined by an operator through blue dyeing indication, so that the accuracy of the operation is improved.
In the preparation process of the method, the water phase used for the first emulsification is ammonium carbonate solution, the solution can form a plurality of small holes on the surface of the microsphere, the holes are beneficial to slow release of the dye wrapped in the microsphere, in addition, the ultrasonic imaging effect can be enhanced, and the effect is stable along with the time.
Compared with the prior art, the invention has the beneficial effects that:
1. the multifunctional ultrasonic contrast agent can be more accurately and effectively positioned and firmly combined on the surface of lymphatic endothelial cells, obviously enhanced tumor metastasis lymph nodes are observed through an ultrasonic contrast mode, sentinel lymph nodes can be indicated in the operation, the contrast agent not only has stronger targeting capability, but also has the functions of ultrasonic contrast imaging and indication in the operation, and has the effect of preventing tumor metastasis, and the multifunctional ultrasonic contrast agent has the blue stain tracing effect, the ultrasonic imaging effect and the treatment effect.
2. The preparation method of the invention utilizes double emulsification method and vacuum freeze drying technology, adds fat-soluble blue dye Sudan black into PLGA ultrasonic contrast agent, loads the Sudan black on PLGA ultrasonic microbubble wall to prepare the ultrasonic contrast agent SB-PLGA with blue dye indication function, and uses EDC/NHS as coupling activator, and covalently connects VEGFR-3 on the surface, so that the macromolecule contrast agent can be effectively and firmly combined to the surface of lymphatic endothelial cell, and has stronger targeting ability.
3. PLGA and VEGFR-3 adopted by the invention are biological materials with good biocompatibility and can not generate toxicity to human bodies; the adopted synthetic method is simple, easy to operate and suitable for large-scale production.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
Fig. 1 is a schematic structural diagram of the multifunctional targeted ultrasound contrast agent in example 1;
FIG. 2 is a scanning electron micrograph of the multifunctional targeted ultrasound contrast agent of example 1;
FIG. 3 is a diagram of a lyophilized powder of the multifunctional targeted ultrasound contrast agent in example 1;
FIG. 4 is a particle size distribution diagram of the multifunctional targeted ultrasound contrast agent in example 1;
FIG. 5 is a potential diagram of the multifunctional targeted ultrasound contrast agent of example 1;
FIG. 6 is a development image of lymph node contrast with the multifunctional targeted ultrasound contrast agent of example 1;
FIG. 7 is a diagram of intraoperative blue-stained lymph nodes with the multifunctional targeted ultrasound contrast agent of example 1;
FIG. 8 is a blue stained lymph node gross specimen of the multifunctional targeted ultrasound contrast agent in example 1;
FIG. 9 is a blue stained lymph node frozen section view of the multifunctional targeted ultrasound contrast agent of example 1;
FIG. 10 is a fluorescent image of the binding of the multifunctional targeted ultrasound contrast agent to human lymphatic endothelial cells in example 1;
FIG. 11 is a confocal fluorescence development of the multifunctional targeted ultrasound contrast agent combined with human lymphatic endothelial cells in example 1;
FIG. 12 is a particle size distribution diagram of the multifunctional targeted ultrasound contrast agent in example 2;
FIG. 13 is a potential diagram of the multifunctional targeted ultrasound contrast agent in example 2;
fig. 14 is a particle size distribution diagram of the multifunctional targeted ultrasound contrast agent in example 3.
Detailed Description
In order to facilitate understanding of the invention, the invention will be described more fully and in detail with reference to the accompanying drawings and preferred embodiments, but the scope of the invention is not limited to the specific embodiments below.
Unless otherwise defined, all terms of art used hereinafter have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention.
Unless otherwise specifically stated, various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or can be prepared by existing methods.
Example 1:
the invention relates to a multifunctional targeted ultrasound contrast agent, and a preparation method of the multifunctional targeted ultrasound contrast agent, wherein the preparation method comprises the following steps:
(1) dissolving the organic phase: dissolving 0.5g of polylactic acid-glycolic acid copolymer (PLGA-COOH, the polymerization ratio of carboxyl to hydroxyl is 50: 50) in 10mL of dichloromethane, adding 20mg of Sudan black, and fully stirring until the Sudan black is completely dissolved to obtain a mixed solution;
(2) emulsification: adding 1mL of ammonium carbonate solution with the mass concentration of 4% into the mixed solution obtained in the step (1), performing ultrasonic emulsification for 30s by using a sound vibration instrument with the power of 110W to obtain a primary emulsion, adding 50mL of polyvinyl alcohol solution with the mass concentration of 4%, and performing homogenization treatment for 5min by using a homogenizer with the rotating speed of 9000rpm to obtain a double emulsion;
(3) and (3) volatilizing an organic phase: adding 100mL of isopropanol solution with the mass concentration of 2% into the double emulsion obtained in the step (2), magnetically stirring for 2.5h at room temperature to solidify the surface of the microsphere, naturally volatilizing dichloromethane as much as possible, centrifuging at high speed (5000rpm), taking the precipitate, washing with double distilled water, repeating for multiple times, collecting the microsphere, and carrying out vacuum freeze drying at-80 ℃ for 48h to obtain the non-targeted ultrasound contrast agent with the polylactic acid-glycolic acid copolymer loaded with Sudan black;
(4) coupling activation and centrifugation: dispersing and dissolving the non-targeted ultrasonic contrast agent obtained in the step (3) in an MES buffer solution, adding a coupling activator EDC/NHS according to the mass ratio of EDC to NHS of 1: 3 and the mass ratio of EDC to the non-targeted ultrasonic contrast agent of 1: 10, incubating at 0 ℃ for 120min, centrifuging in the MES buffer solution (3000rpm), rinsing for 3 times, and removing unreacted EDC/NHS to obtain a high-molecular contrast agent; the pH of the MES buffer used in this step was 6.0;
(5) incubating antibody, centrifuging: dispersing and dissolving the high molecular contrast agent obtained after centrifugation in the step (4) in an MES buffer solution with the pH value of 8.0, adding the anti-human VEGFR-3 monoclonal antibody according to the mass ratio of the anti-human VEGFR-3 monoclonal antibody to the high molecular contrast agent of 1: 2000, uniformly mixing, incubating for 60min at the temperature of 0 ℃, then centrifuging in the MES buffer solution (3000rpm), rinsing for 3 times, taking the precipitate, performing vacuum freeze drying at the temperature of-80 ℃ for 48h, and then filling fluorocarbon gas to obtain the multifunctional targeted ultrasound contrast agent (freeze-dried powder); the MES buffer used in this step had a pH of 8.0.
The structure of the multifunctional targeted ultrasound contrast agent obtained in the present embodiment is schematically shown in fig. 1, and the scanning electron micrograph is shown in fig. 2. As can be seen from the figure, the multifunctional targeted ultrasound contrast agent of the embodiment includes a polylactic acid-glycolic acid copolymer, wherein fluorocarbon gas is filled in the polylactic acid-glycolic acid copolymer to form a polylactic acid-glycolic acid copolymer microsphere, sudan black dye is loaded in the polylactic acid-glycolic acid copolymer, and a carboxyl terminal of the polylactic acid-glycolic acid copolymer is coupled with an anti-human VEGFR-3 monoclonal antibody through a covalent bond.
The lyophilized powder entity of the multifunctional targeted ultrasound contrast agent obtained in this example is shown in fig. 3, and the entity is blue.
The particle size distribution of the multifunctional targeted ultrasound contrast agent obtained in this example is shown in fig. 4, and it can be seen from fig. 2 that the particle size of the contrast agent is about 1.2 μm.
The potential distribution of the multifunctional targeted ultrasound contrast agent obtained in the example is shown in fig. 5, and the potential of the contrast agent is-12.3 mV, which shows that the contrast agent has excellent stability.
Experiment one:
the multifunctional targeted ultrasound contrast agent of the embodiment can be applied to ultrasound contrast and intra-operative exploration of sentinel lymph nodes of tumors, and comprises the following specific steps:
VX2 tumor-bearing rabbits; dissolving 0.1g of the multifunctional targeted ultrasound contrast agent obtained in example 1 in 2mL of physiological saline to obtain 8 New Zealand white rabbits with unlimited male and female parts, and cutting out tumor tissue blocks with 1mm of vigorous growth2The tumor model is established by planting the model under the skin of the right thigh of the rabbit, and the model building position is obviously protruded after about 1 week to obtain the tumor model.
Preparing a Philips iU22 ultrasonic instrument, wherein the frequency of a probe is 7-10 MHz, and performing harmonic imaging. VX2 tumor-bearing rabbits 8 had a body mass of about 2.5 kg. The popliteal fossa area was depilated with 8% sodium sulfide prior to ultrasonography, and the experimental animals were anesthetized with 1mL/kg intramuscular injection of 3% sodium pentobarbital. Then injecting the contrast agent dissolved by physiological saline into the subcutaneous space of the rabbit foot pad according to the dosage of 0.5mL/kg, massaging the foot pad, and simultaneously carrying out the popliteal lymph node harmonic imaging. The same amount of physiological saline is injected into the contralateral foot pad, and the foot pad is massaged to carry out harmonic imaging as a contrast. The resulting image is shown in FIG. 6, where it can be seen that the tumor lymph node enhancement starts at the edge, fills rapidly into the center, and finally the entire lymph node is uniformly visualized.
After 30 minutes, the imaged experimental rabbit was subjected to popliteal lymphadenectomy, bilateral lymph nodes were excised as shown in fig. 7 and 8, an "L" incision was made in the inguinal region for about 8cm, subcutaneous tissue was isolated before the fascia, the inguinal lymph node was fully exposed, the inguinal lymph node staining was observed, and the surgically excised lymph node was subjected to HE staining of a cryosection. As shown in FIG. 7 and FIG. 8, it can be seen that the lymph nodes injected with the targeted contrast agent have good staining effect in the popliteal lymphadenectomy, and the group injected with the normal saline on the opposite side has no blue staining. As shown in FIG. 9, cryo-section HE staining revealed that the contrast agent was present in the lymph nodes in the lymph sinus with a large number of macrophages entering, with inguinal lymph node clearing, and no blue staining of the second lymph node.
Experiment two:
the multifunctional targeted ultrasound contrast agent can be combined with human lymphatic endothelial cells in a targeted manner, and comprises the following specific steps:
culturing human lymphatic endothelial cells, and conventionally culturing by adopting a high-glucose DMEM culture solution containing 10% fetal calf serum; digesting the cells by using 0.25% trypsin, and subculturing for 2-3 generations; sterilizing a clean cover glass and then placing the sterilized cover glass at the bottom of a 6-hole plate; taking cells in logarithmic growth phase at 1 × 104And (3) inoculating the cells in each hole according to the density of the holes, and continuously culturing for 24 hours after the cells adhere to the wall to prepare the adult lymphatic endothelial cell slide.
200uL of the multifunctional targeted ultrasound contrast agent of the present example was added, and 2mL of cell culture medium was added to each well, followed by addition of CO2Incubate in incubator for 1 h. After 1h, the slide was removed, each slide was washed 5 times with PBS buffer, and a large amount of targeted contrast agent was observed to form a ring under a fluorescence microscope and emit intense red fluorescence (fig. 10).
The fluorescent dye DAPI is used for marking human lymphatic endothelial cells on the cell slide in advance, the DiI is used for marking the macromolecular contrast agent, the processing and the like are the same as the above operations, and the laser confocal microscope is used for observing the combination condition, so that the distribution condition of the contrast agent and the human lymphatic endothelial cells can be more clearly positioned than an inverted fluorescence microscope. The results are shown in fig. 11, where a larger amount of targeted contrast agent surrounded the cell periphery like a rosette in the targeted contrast agent experimental group.
Experiments prove that the multifunctional ultrasonic contrast agent can be more accurately and effectively positioned and firmly combined on the surface of lymphatic endothelial cells, obviously enhanced tumor metastasis lymph nodes are observed in an ultrasonic contrast mode, sentinel lymph nodes can be indicated in the operation, the contrast agent not only has stronger targeting capability, but also has ultrasonic contrast imaging and intraoperative indication functions, and the multifunctional ultrasonic contrast agent has both blue-staining tracing effect and ultrasonic imaging effect.
Example 2:
the invention relates to a multifunctional targeted ultrasound contrast agent, which is prepared by the following steps:
(1) dissolving the organic phase: dissolving 0.5g of polylactic acid-glycolic acid copolymer (PLGA-COOH, the polymerization ratio of carboxyl to hydroxyl is 50: 50) in 10mL of dichloromethane, adding 20mg of Sudan black, and fully stirring until the Sudan black is completely dissolved to obtain a mixed solution;
(2) emulsification: adding 1mL of ammonium carbonate solution with the mass concentration of 4% into the mixed solution obtained in the step (1), performing ultrasonic emulsification for 40s by using a sound vibration instrument with the power of 110W to obtain a primary emulsion, adding 50mL of polyvinyl alcohol solution with the mass concentration of 4%, and performing homogenization treatment for 5min by using a homogenizer with the rotating speed of 9000rpm to obtain a double emulsion;
(3) and (3) volatilizing an organic phase: adding 100mL of isopropanol solution with the mass concentration of 2% into the double emulsion obtained in the step (2), magnetically stirring for 3 hours at room temperature to solidify the surface of the microsphere, naturally volatilizing dichloromethane as much as possible, centrifuging at a high speed (5000rpm), taking the precipitate, washing with double distilled water, repeating for multiple times, collecting the microsphere, freeze-drying at-80 ℃ for 48 hours, and filling to obtain the polylactic acid-glycolic acid copolymer loaded Sudan black non-targeted ultrasonic contrast agent;
(4) coupling activation and centrifugation: dispersing and dissolving the non-targeted ultrasonic contrast agent obtained in the step (3) in an MES buffer solution, adding a coupling activator EDC/NHS according to the mass ratio of EDC to NHS of 1: 3 and the mass ratio of EDC to the non-targeted ultrasonic contrast agent of 1: 10, incubating at 0 ℃ for 120min, centrifuging in the MES buffer solution (3000rpm), rinsing for 3 times, and removing unreacted EDC/NHS to obtain a high-molecular contrast agent; the pH of the MES buffer used in this step was 6.0;
(5) incubating antibody, centrifuging: dispersing and dissolving the high molecular contrast agent obtained after centrifugation in the step (4) in an MES buffer solution with the pH value of 8.0, adding the anti-human VEGFR-3 monoclonal antibody according to the mass ratio of the anti-human VEGFR-3 monoclonal antibody to the high molecular contrast agent of 1: 2000, uniformly mixing, incubating for 60min at the temperature of 0 ℃, then centrifuging in the MES buffer solution (3000rpm), rinsing for 3 times, taking the precipitate, performing vacuum freeze drying at the temperature of-80 ℃ for 48h, and then filling fluorocarbon gas to obtain the multifunctional targeted ultrasound contrast agent (freeze-dried powder); the MES buffer used in this step had a pH of 8.0.
The multifunctional targeted ultrasound contrast agent comprises a polylactic acid-glycolic acid copolymer, wherein fluorocarbon gas is filled in the polylactic acid-glycolic acid copolymer to form polylactic acid-glycolic acid copolymer microspheres, sudan black dye is loaded in the polylactic acid-glycolic acid copolymer, and an anti-human VEGFR-3 monoclonal antibody is coupled to the carboxyl end of the polylactic acid-glycolic acid copolymer through a covalent bond.
The particle size distribution of the multifunctional targeted ultrasound contrast agent obtained in this example is shown in fig. 12, and it can be seen from fig. 12 that the particle size of the contrast agent is about 1.3 μm.
The potential distribution of the multifunctional targeted ultrasound contrast agent obtained in this example is shown in fig. 13, and it can be seen from the graph that the potential of the contrast agent is-10 mV, which indicates that the stability of the contrast agent is excellent.
Example 3:
the invention relates to a multifunctional targeted ultrasound contrast agent, which is prepared by the following steps:
(1) dissolving the organic phase: dissolving 100mg of polylactic acid-glycolic acid copolymer (PLGA-COOH, the polymerization ratio of carboxyl to hydroxyl is 50: 50) in 2mL of dichloromethane, adding 4mg of Sudan black, and fully stirring until the Sudan black is completely dissolved to obtain a mixed solution;
(2) emulsification: adding 200uL of ammonium carbonate solution with the mass concentration of 4% into the mixed solution obtained in the step (1), performing ultrasonic emulsification for 30s by using a sound vibration instrument with the power of 110W to obtain primary emulsion, adding 10mL of polyvinyl alcohol solution with the mass concentration of 4%, and performing homogenization treatment for 5min by using a homogenizer with the rotating speed of 9000rpm to obtain double emulsion;
(3) and (3) volatilizing an organic phase: adding 20mL of isopropanol solution with the mass concentration of 2% into the double emulsion obtained in the step (2), magnetically stirring for 2h at room temperature to solidify the surface of the microsphere, naturally volatilizing dichloromethane as much as possible, centrifuging at a high speed (5000rpm), taking the precipitate, washing with double distilled water, repeating for multiple times, collecting the microsphere, and freeze-drying at-80 ℃ for 48h to obtain the non-targeted ultrasound contrast agent with the polylactic acid-glycolic acid copolymer coated with Sudan black;
(4) coupling activation and centrifugation: dispersing and dissolving the non-targeted ultrasonic contrast agent obtained in the step (3) in an MES buffer solution, adding a coupling activator EDC/NHS according to the mass ratio of EDC to NHS of 1: 3 and the mass ratio of EDC to the non-targeted ultrasonic contrast agent of 1: 10, incubating at 0 ℃ for 120min, centrifuging in the MES buffer solution (3000rpm), rinsing for 3 times, and removing unreacted EDC/NHS to obtain a high-molecular contrast agent; the pH of the MES buffer used in this step was 6.0;
(5) incubating antibody, centrifuging: dispersing and dissolving the high molecular contrast agent obtained after centrifugation in the step (4) in an MES buffer solution with the pH value of 8.0, adding the anti-human VEGFR-3 monoclonal antibody according to the mass ratio of the anti-human VEGFR-3 monoclonal antibody to the high molecular contrast agent of 1: 2000, incubating for 60min at the temperature of 0 ℃, then centrifuging (3000rpm) in the MES buffer solution, rinsing for 3 times, collecting the high molecular contrast agent, dispersing and dissolving the high molecular contrast agent in the MES buffer solution, centrifuging in the MES buffer solution, rinsing for 3 times, taking the precipitate, performing vacuum freeze drying, and filling fluorocarbon gas to obtain the multifunctional targeted ultrasound contrast agent.
The multifunctional targeted ultrasound contrast agent obtained in the embodiment comprises a polylactic acid-glycolic acid copolymer, wherein fluorocarbon gas is filled in the polylactic acid-glycolic acid copolymer to form a polylactic acid-glycolic acid copolymer microsphere, sudan black dye is loaded in the polylactic acid-glycolic acid copolymer, and a carboxyl end of the polylactic acid-glycolic acid copolymer is coupled with an anti-human VEGFR-3 monoclonal antibody through a covalent bond.
The particle size distribution of the multifunctional targeted ultrasound contrast agent obtained in the embodiment is shown in the figure, and the particle size of the contrast agent is about 1.1 μm as can be seen from fig. 14.
Claims (6)
1. The multifunctional targeted ultrasound contrast agent is characterized by comprising a polylactic acid-glycolic acid copolymer, wherein fluorocarbon gas is filled in the polylactic acid-glycolic acid copolymer to form polylactic acid-glycolic acid copolymer microspheres, Sudan black dye is loaded in the polylactic acid-glycolic acid copolymer, and the carboxyl end of the polylactic acid-glycolic acid copolymer is coupled with an anti-human VEGFR-3 monoclonal antibody through a covalent bond; the particle size of the microspheres of the multifunctional ultrasonic contrast agent is 1-2 μm; the polymerization ratio of carboxyl and hydroxyl in the polylactic acid-glycolic acid copolymer is 50: 50.
2. The preparation method of the multifunctional targeted ultrasound contrast agent as claimed in claim 1, comprising the following steps:
(1) dissolving a polylactic acid-glycolic acid copolymer in dichloromethane, adding Sudan black, and stirring until the mixture is completely dissolved to obtain a mixed solution;
(2) adding an ammonium carbonate solution into the mixed solution obtained in the step (1), performing ultrasonic emulsification to obtain a primary emulsion, adding a polyvinyl alcohol solution, and performing homogenization treatment to obtain a double emulsion;
(3) adding an isopropanol solution into the double emulsion obtained in the step (2), performing magnetic stirring, centrifuging, washing the precipitate with double distilled water, and performing vacuum freeze drying to obtain the polylactic acid-glycolic acid copolymer-loaded Sudan black non-targeted ultrasonic contrast agent;
(4) dispersing and dissolving the non-targeted ultrasound contrast agent obtained in the step (3) in an MES buffer solution, adding a coupling activator EDC/NHS for incubation, then centrifuging in the MES buffer solution, and removing unreacted EDC/NHS after rinsing to obtain a macromolecular contrast agent; the pH value of the MES buffer solution is 5.9-6.3, the incubation temperature is 0-4 ℃, the incubation time is 120-130 min, the centrifugal speed is 3000-5000 rpm, and the rinsing times are 3-5; the mass ratio of EDC to NHS is 1: 3; the mass ratio of EDC to non-targeted ultrasound contrast agent is 1: 10;
(5) dispersing and dissolving the high molecular contrast agent obtained in the step (4) in MES buffer solution, adding an anti-human VEGFR-3 monoclonal antibody, uniformly mixing, incubating, centrifuging in the MES buffer solution, rinsing, taking the precipitate, performing vacuum freeze drying, and then filling fluorocarbon gas to obtain the multifunctional targeted ultrasound contrast agent; the pH value of the MES buffer solution is 7.9-8.3, the incubation temperature is 0-4 ℃, the incubation time is 60-70 min, the centrifugal speed is 3000-5000 rpm, and the rinsing times are 3-5; the mass ratio of the anti-human VEGFR-3 monoclonal antibody to the macromolecular contrast agent is 1: 2000.
3. The preparation method according to claim 2, wherein in the step (1), a ratio of a mass of the polylactic acid-glycolic acid copolymer to a volume of dichloromethane is 50: 1 in mg/mL, and in the step (1), a ratio of a mass of sudan black to a volume of dichloromethane is 2: 1 in mg/mL.
4. The preparation method according to claim 2, wherein in the step (2), the mass concentration of the ammonium carbonate solution is 4%, the volume ratio of the ammonium carbonate solution to dichloromethane is 1: 10, the power of ultrasonic emulsification is 110W, and the time of ultrasonic emulsification is 30-40 s; the mass concentration of the polyvinyl alcohol solution is 4%, the volume ratio of the polyvinyl alcohol solution to the dichloromethane solvent is 5: 1, the rotation speed of homogenization treatment is 9000-10000 rpm, and the time of the homogenization treatment is 5-8 min.
5. The preparation method according to claim 2, wherein in the step (3), the mass concentration of the isopropanol solution is 2%, the volume ratio of the isopropanol solution to the dichloromethane solvent is 10: 1, and the magnetic stirring time is 2-3 h.
6. The preparation method according to any one of claims 2 to 5, wherein in the step (3) and/or the step (5), the temperature of vacuum freeze drying is-80 ℃, and the time of vacuum freeze drying is 40-50 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910615944.2A CN110327472B (en) | 2019-07-09 | 2019-07-09 | Multifunctional targeted ultrasound contrast agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910615944.2A CN110327472B (en) | 2019-07-09 | 2019-07-09 | Multifunctional targeted ultrasound contrast agent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110327472A CN110327472A (en) | 2019-10-15 |
| CN110327472B true CN110327472B (en) | 2022-03-15 |
Family
ID=68144854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910615944.2A Active CN110327472B (en) | 2019-07-09 | 2019-07-09 | Multifunctional targeted ultrasound contrast agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110327472B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112933248B (en) * | 2021-02-04 | 2022-09-30 | 北京大学第三医院（北京大学第三临床医学院） | Sentinel lymph node double-development tracer, preparation method and application |
-
2019
- 2019-07-09 CN CN201910615944.2A patent/CN110327472B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| "多功能超声造影剂显像及治疗肿瘤转移淋巴结实验研究";牛诚诚;《中国博士学位论文全文数据库医药卫生科技辑》;20140315(第03期);摘要，正文第24-26页 * |
| "携抗HER2抗体和抗VEGFR2抗体聚乳酸羟基乙酸双靶向纳米高分子超声造影剂制备及体外实验研究";李晓钰等;《上海交通大学学报医学版》;20161231;第36卷(第1期);摘要，第24-25页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110327472A (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69735901T2 (en) | ENHANCING OR IN CONNECTION WITH DIAGNOSTIC / THERAPEUTIC AGENTS | |
| CN106267241B (en) | The multi-functional multi-modal fluorescent dye with tumour-specific targeting inversion of phases nanosphere photoacoustic contrast agent of one kind and its application | |
| Wheatley et al. | Comparison of in vitro and in vivo acoustic response of a novel 50: 50 PLGA contrast agent | |
| Lathia et al. | Polymeric contrast agent with targeting potential | |
| US8940277B2 (en) | Intracellular microbubble for imaging an anatomical site | |
| US20150125398A1 (en) | Multimodal imaging methods using mesoporous silica nanoparticles | |
| Li et al. | A preliminary study of photoacoustic/ultrasound dual-mode imaging in melanoma using MAGE-targeted gold nanoparticles | |
| CN112587677B (en) | iRGD magnetic targeting microbubble contrast agent and application thereof | |
| CN108635596A (en) | A kind of acoustic contrast agent and preparation method thereof for stem cell ultrasound tracer | |
| CN104288786B (en) | Tumor targeted diagnosing and treating system based on near-infrared quantum dot and preparation method thereof | |
| CN110327472B (en) | Multifunctional targeted ultrasound contrast agent and preparation method thereof | |
| CN105999311B (en) | targeted developer for diagnosing achilles tendonitis and preparation method thereof | |
| CN111632154A (en) | Phase-transition nanobubble, preparation method and application thereof | |
| CN110404082A (en) | A kind of targeted ultrasound inversion of phases bimodal imaging nano-contrast agent and its preparation method and application | |
| Chen et al. | Targeting nanoparticle-conjugated microbubbles combined with ultrasound-mediated microbubble destruction for enhanced tumor therapy | |
| CN113827742A (en) | Breast cancer sentinel lymph node tracing targeting molecular probe and preparation method thereof | |
| CN102772808B (en) | A kind of multi-modality imaging microbubble construction, Preparation method and use | |
| CN109620973A (en) | For targeting the nano drug-carrying compound and preparation method of diagnosis and treatment artery sclerosis | |
| CN111558052B (en) | Bispecific PSMA/GRPr targeted bimodal imaging nano contrast agent and preparation method and application thereof | |
| CN105536000B (en) | A kind of acoustic contrast agent and its preparation method and application based on pentaerythritol ester | |
| CN103784422B (en) | A kind of year rtPA nanoparticle and preparation method thereof | |
| Lathia et al. | Surface modification of polymeric contrast agents for cancer targeting | |
| Hartanto et al. | Nanoparticles for ultrasound-guided imaging of cell implantation | |
| KR101446681B1 (en) | Ultrasound contrast agent capable of liver cancer specific targetting and method for preparing the same | |
| CN109395102B (en) | Pancreatic cancer double-targeting polymer magnetic nanoparticle and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |